Mary Odowd, MD
Internal Medicine · Chesterfield, MONPI 1235214214
Payments from drug & device makers
Across 212 payments — averaging $16.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$439
- Novartis$415
- Amarin Pharma, Inc.$379
- Lilly USA, LLC$364
- Sunovion Pharmaceuticals Inc.$251
- AstraZeneca$223
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,49698%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 28 | $439 |
| Novartis | 27 | $415 |
| Amarin Pharma, Inc. | 27 | $379 |
| Lilly USA, LLC | 17 | $364 |
| Sunovion Pharmaceuticals Inc. | 13 | $251 |
| AstraZeneca | 14 | $223 |
| UCB, Inc. | 10 | $176 |
| Eisai Inc. | 10 | $144 |
| Astellas Pharma US Inc | 4 | $137 |
| Merck | 7 | $120 |
| Amgen | 8 | $116 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Pfizer | 4 | $73 |
| AbbVie(2 entities) | 4 | $68 |
| Avanir Pharmaceuticals, Inc. | 4 | $63 |
| Currax Pharmaceuticals LLC | 5 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $48 |
| Exact Sciences | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Abbott | 2 | $35 |
| Greenwich Biosciences, Inc. | 1 | $32 |
| Boehringer Ingelheim | 1 | $22 |
| GSK | 1 | $21 |
| Acadia Pharmaceuticals Inc | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Optos, Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Neurocrine Biosciences, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$3,576 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $13,768 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 14 | $3,818 |
| Irbesartan | 116 | $1,750 |
| Potassium Chloride | 48 | $1,741 |
| SynthroidLevothyroxine Sodium | 15 | $1,531 |
| Amlodipine Besylate | 171 | $1,032 |
| Lisinopril | 135 | $932 |
| Rosuvastatin Calcium | 57 | $708 |
| Pravastatin Sodium | 78 | $697 |
| Memantine Hcl | 29 | $666 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $665 |
| Atorvastatin Calcium | 116 | $650 |
| Levothyroxine Sodium | 91 | $650 |
| Metoprolol Succinate | 56 | $638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $13,76818 claims |
| GSKArexvy | $21 | $3,81814 claims |
| AbbVieSynthroid | $68 | $1,53115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.
Other internal medicine in Chesterfield
- Jianbo WangChesterfield$643K
- Timothy SmithSaint Peters$21.4M
- Craig DietzKansas City$4M
- Michael ReschakSaint Louis$3.1M
- Dima DandachiColumbia$1.2M
- Santosh SharmaKansas City$782K
- David PrelutskySaint Louis$575K
- Danish JabbarSaint Louis$510K
- Dubert GuerreroIndependence$369K
- Hany SalamaSaint Louis$279K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.